Lymphoma Clinical Trials

Showing 241-260 of 3,379 trials

T Cell Lymphoma -Stratified Therapy After Response to First-line Treatment-NR

NCT07470996

This study is a multicenter, two-arm, prospective clinical trial, comprising two groups: the allogeneic hematopoietic stem cell transplantation group (Allo-HSCT) and the alternative salvage regimens. It aims to evaluate the efficacy and safety of Allo-HSCT and alternative salvage regimens in the treatment of peripheral T-cell lymphoma that has achieved no response (NR) after first-line therapy. During the screening/baseline period, informed consent will be obtained, and inclusion/exclusion criteria will be verified. Group assignment (Allo-HSCT vs. alternative salvage regimens) will be determined taking into account the availability of a matched donor and the patient's preference. The study plans to enroll 29 patients in each group. Data on demographics and medical history will be collected, and assessments including vital signs, physical examination, PET-CT, bone marrow aspiration smear, flow cytometry, and bone marrow pathology will be performed.

Peripheral T Cell Lymphoma

Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine58 participantsStarted Oct 2025

Shanghai, Shanghai Municipality, China

Active Not RecruitingPhase 1

A Study of JNJ-80948543 in Combination With Other CD3 T-Cell Engagers in Participants With Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma (R/R B-Cell NHL)

NCT06660563

The purpose of this study is to determine the recommended phase 2 regimen (RP2R) for JNJ-80948543 in combination with JNJ-75348780 (Part 1: Dose Escalation) and to further assess the safety of JNJ-80948543 at the RP2R in combination with JNJ-75348780 (Part 2: Dose Expansion).

Lymphoma, Non-Hodgkin

Janssen Research & Development, LLC19 participantsStarted Oct 2024

Concord, Australia • Fitzroy, Australia • North Ryde, Australia +8 more locations

T Cell Lymphoma -Stratified Therapy After Response to First-line Treatment-NR

A Study of JNJ-80948543 in Combination With Other CD3 T-Cell Engagers in Participants With Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma (R/R B-Cell NHL)

Related Searches

Low Dose Mosunetuzumab for the Treatment of Patients With Indolent B-Cell Lymphoma

Nemtabrutinib With Rituximab for the Treatment of Patients With Mantle Cell Lymphoma

GB5005 CART-cell Injection in the Treatment of Patients With CD19-positive RR B-NHL

Epcoritamab in Patients With Follicular Lymphoma Not Accomplishing a CR With Upfront Chemoimmunotherapy

Odronextamab in Low Tumor Volume Advanced FL

Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma

Acalabrutinib and Durvalumab in Primary and Secondary Central Nervous System Lymphoma

CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies

A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

Venetoclax Basket Trial for High Risk Hematologic Malignancies

A Long-term Extension Study of PCI-32765 (Ibrutinib)

A Study of Zilovertamab Vedotin (MK-2140) as Monotherapy and in Combination in Participants With Aggressive and Indolent B-cell Malignancies (MK-2140-006)

A Study to Evaluate the Safety and Preliminary Efficacy of ATA3219 in Participants With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma

Lenalidomide and Combination Chemotherapy (DA-EPOCH-R) in Treating Patients With MYC-Associated B-Cell Lymphomas

National Epidemiology of Cutaneous Lymphomas

Economic Analysis of Early vs Delayed Therapy in Newly Diagnosed Asymptomatic High-Risk Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma:

IGNITE: Study of Tirabrutinib vs Rituximab/Temozolomide for Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL)

Safety and Efficacy of OC-1 Therapy in Patients With R/R T-ALL/LL